This article was originally published in The Gray Sheet
BD inks agreement with Germany-based Haselmeier GmbH to form a joint venture for the design, development and exclusive distribution of auto-injecting pen devices, the companies announce Oct. 5. The Swiss-based venture, BD/Medico GmbH, will design hidden-needle injection devices for the self-administration of parenteral drugs. BD is targeting recipients of growth hormones, fertility agents, alpha-interferon for hepatitis, beta-interferon for multiple sclerosis and low molecular weight heparin for deep vein thrombosis. While the devices will be immediately available to pharmaceutical companies, BD estimates a timeframe of 18-24 months before the devices make it to the U.S. market
You may also be interested in...
The AAM has insisted that the US Supreme Court should uphold the inter partes review framework, in an amicus brief filed as part of litigation that potentially threatens hundreds of IPR decisions.
The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.